Trial Profile
An Open-Label, Randomized, Multicenter Phase II Trial Comparing the Depletion of Malignant Stem Cells With Dasatinib vs. Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Nov 2023
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Imatinib
- Indications Chronic myeloid leukaemia
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 04 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record record.
- 10 Dec 2013 Clinical results presented at the 56th Annual Meeting and Exposition of the American Society of Hematology.
- 14 Jun 2013 Results presented at the 18th Congress of the European Haematology Association.